NCT01845350View on ClinicalTrials.gov

Safety of Autologous M2 Macrophage in Treatment of Non-Acute Stroke Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

October 31, 2015

Conditions
Ischemic StrokeHemorrhagic Stroke
Interventions
OTHER

M2 macrophage introduction

"* Generation of autologous M2 macrophages from peripheral blood of non-acute stroke patients~* Intrathecal introduction of autologous M2 macrophages"

Trial Locations (1)

630099

Research Institute of Clinical Immunology, Russian Academy of Medical Sciences (Siberian Branch), Novosibirsk

All Listed Sponsors
lead

Siberian Branch of the Russian Academy of Medical Sciences

OTHER

NCT01845350 - Safety of Autologous M2 Macrophage in Treatment of Non-Acute Stroke Patients | Biotech Hunter | Biotech Hunter